Application of astaxanthin in preparation of drugs for prevention and treatment of glomerular fibrosis and edema

A technology of glomerulus and astaxanthin, which is applied in the field of preparation, treatment, prevention and treatment of diabetic nephropathy glomerular fibrosis and edema, and can solve metabolic abnormalities, abnormal metabolism of vasoactive substances, renal hemodynamics Abnormal and other issues

Inactive Publication Date: 2016-01-20
NINGBO UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] 2. Abnormal renal hemodynamics
[0008] 3. Metabolic abnormalities caus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astaxanthin in preparation of drugs for prevention and treatment of glomerular fibrosis and edema
  • Application of astaxanthin in preparation of drugs for prevention and treatment of glomerular fibrosis and edema
  • Application of astaxanthin in preparation of drugs for prevention and treatment of glomerular fibrosis and edema

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] The preventive intervention effect of astaxanthin on type 2 diabetes

[0075] figure 1 The experimental flow chart in Example 1 is shown. Specifically, 20 healthy male SD rats were randomly divided into five experimental groups, namely: group A (normal control group), group B (simple high-fat group), group C (high-fat + STZ group), Group D (high fat + astaxanthin prevention + STZ group), E group (high fat + astaxanthin prevention group), 4 rats in each group. The normal control group was fed normal rat diet for 10 weeks, and the other groups were fed high-fat diet simultaneously. From the 7th week, rats in group D and E were treated with astaxanthin at a dose of 25 mg / kg For prevention, groups A, B, and C were given the same amount of normal saline for a period of 4 weeks. After the prevention, the rats in each group were fasted for 12 hours. The rats in groups C and D were injected intraperitoneally with 1% STZ citrate buffer at a dose of 25 mg / kg on the next day, and r...

Embodiment 2

[0078] The therapeutic effect of astaxanthin on type 2 diabetes

[0079] This experiment was carried out simultaneously with the aforementioned preventive effect experiment. Such as the experimental flowchart (see figure 2 ) Shown: Take 20 male healthy SD rats, first randomly select 4 as the normal control group, and feed them with normal rat diet for 6 weeks. The rats in the remaining groups were simultaneously fed with high-fat diet for 6 weeks and then injected intraperitoneally with 1% STZ citrate buffer at a dose of 25 mg / kg. Subsequently, the tails were cut and blood was taken to measure random blood glucose values. Eight animals with random blood glucose values ​​≥ 11.1 mol / L were selected as experimental rats, and they were randomly divided into a diabetes group and a treatment group with 4 rats each. The dose of astaxanthin in the treatment group was 25mg / kg; the other groups were given the same amount of normal saline at the same time, and each mouse was given intraga...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of astaxanthin in preparation of pharmaceutical compositions for inhibiting alpha-SMA and FN expression in prevention and treatment of glomerular fibrosis and edema, and discloses a pharmaceutical composition for prevention and treatment of glomerular fibrosis and edema. And the pharmaceutical composition is characterized by containing astaxanthin.

Description

Technical field [0001] The present invention relates to the application of astaxanthin in the preparation, treatment, prevention and treatment of diabetic nephropathy and glomerular fibrosis and edema. More specifically, the present invention relates to astaxanthin in the preparation of α-SMA in inhibiting glomerular fibrosis and edema. And FN-expressed drugs. Background technique [0002] With the development of the global economy and the improvement of human material living standards, the prevalence of diabetes is getting higher and higher. Diabetic Nephropathy (DN) is one of the most serious chronic complications of diabetes and an important cause of end-stage renal disease (EndStageRenalDisease, ESRD). DN is recognized as one of the main microvascular complications of diabetes. According to the latest data from the International Diabetes Federation (IDF) in 2013, there are currently 366 million people with diabetes in the world, and there are approximately 114 million people...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/122A61P13/12A61P3/10
Inventor 步世忠洪梦琪陈争跃吴佳燕王福艳包蓓艳
Owner NINGBO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap